NCT01666444.
Trial name or title | VTX‐2337 and pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer |
Methods | Phase II double blind multicentre RCT |
Participants | 210 women with PR ROC |
Interventions | VTX‐2337 + PLD versus PLD + placebo |
Outcomes | Primary: OS Secondary: PFS, toxicity, ORR, DCR |
Starting date | Aug 2012 |
Contact information | Bradley Monk: bradley.monk@chw.edu |
Notes | End Date: Mar 2016 |